Study Evaluating the Safety and Efficacy With Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

Study Summary

This is a single arm, open-label, single center study to determine the safety and efficacy of Anti-CD19 CAR-T cells in patients with relapsed or refractory acute lymphoblastic leukemia and Lymphomas.

Interventions

Study Locations

Facility	City	State	Country
The First Affiliated Hospital of Nangchang University	Nanchang	Jiangxi	China

Official Trial Information

View on ClinicalTrials.gov